source
- First Tracks reports positive early-stage results for celiac drug ANB033First Tracks Biotherapeutics announced that its experimental celiac disease drug ANB033 showed statistically significant improvement in a six‑week early‑stage trial compared with placebo. The trial…
- Undecimal Bio raises $18 million to expand siRNA platform beyond liver diseasesUndecimal Bio, founded by Yaniv Erlich and Shaul Ilan, announced a new financing round that brings in $18 million. The capital will support the company’s effort to develop siRNA therapeutics for ta…